2013
2012
- October 29
- Announcement of FY2012 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
- October 26
- Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine
- October 19
- Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
- October 10
- Outcome of Global Phase III (EPPIC) Studies
- October 1
- Outsourcing of Logistics Operations
- September 28
- Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
- September 20
- Launch of "Simponi”, a human TNFα monoclonal antibody in Indonesia
- September 13
- MAINTATE Tablets: Selective β1 Antagonist
Notice regarding application for additional indication for chronic atrial fibrillation
- August 31
- Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
- August 31
- Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation
- August 28
- Launch of TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
- July 31
- Announcement of FY2012 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
- July 23
- Launch of Tranquilizer, DEPAS TABLETS 0.25 mg
- July 6
- Launch of Argatroban, a Selective Antithrombin Agent, in UK
- June 29
- Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
- June 6
- Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
- June 1
- Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
- May 15
- Notice Regarding Transfer of Fine Chemical Operations
- May 9
- Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia
- May 8
- Announcement of Financial Results for FY2011
⇒R&D Pipeline "State of New Product Development"
- May 8
- Notice of Dividend of Retained Earnings
- May 8
- New Organization in Plasma Fractionation Operations
Establishment of “Japan Blood Products Organization”
- May 8
- Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
A New Option to Shorten Infusion Time
- May 8
- Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
Lifting of Condition on Approval for Psoriasis
- May 7
- VIVUS gains NDA approval for TA-1790 in the US
- March 29
- Launch of "SIMPONI”, a human TNFα monoclonal antibody in Taiwan
- March 21
- “IMUSERA Capsules 0.5mg” Multiple Sclerosis Treatment AgentNotice regarding revision of “warnings” and “important basic precautions” sections of prescribing information
- March 7
- Conclusion of Research Collaboration Agreement for Next-Generation Vaccines
- March 6
- Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan
Companies conclude joint sales agreement for two treatments
for type 2 diabetes mellitus - MP-513 and TA-7284
- January 31
- Announcement of FY2011 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
- January 16
- Conclusion of Licensing Agreement for Hib Vaccine
